BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

43 related articles for article (PubMed ID: 15271314)

  • 1. Construction of the metabolic reprogramming-associated gene signature for clear cell renal cell carcinoma prognosis prediction.
    Tai R; Leng J; Li W; Wu Y; Yang J
    BMC Urol; 2023 Sep; 23(1):147. PubMed ID: 37715154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Clinical and Molecular Features in the VHL Renal Cancers; Close or Distant Relatives with Sporadic Clear Cell Renal Cell Carcinoma?
    Cinque A; Minnei R; Floris M; Trevisani F
    Cancers (Basel); 2022 Oct; 14(21):. PubMed ID: 36358771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aryl Hydrocarbon Receptor Mechanisms Affecting Chronic Kidney Disease.
    Curran CS; Kopp JB
    Front Pharmacol; 2022; 13():782199. PubMed ID: 35237156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Von Hippel-Lindau Disease: Current Challenges and Future Prospects.
    Gläsker S; Vergauwen E; Koch CA; Kutikov A; Vortmeyer AO
    Onco Targets Ther; 2020; 13():5669-5690. PubMed ID: 32606780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sunitinib for the treatment of benign and malignant neoplasms from von Hippel-Lindau disease: A single-arm, prospective phase II clinical study from the PREDIR group.
    Oudard S; Elaidi R; Brizard M; Le Rest C; Caillet V; Deveaux S; Benoit G; Corréas JM; Benoudiba F; David P; Gaudric A; Hammel P; Joly D; Timsit MO; Méjean A; Richard S
    Oncotarget; 2016 Dec; 7(51):85306-85317. PubMed ID: 27852035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recommendations for measurement of tumour vascularity with positron emission tomography in early phase clinical trials.
    Aboagye EO; Gilbert FJ; Fleming IN; Beer AJ; Cunningham VJ; Marsden PK; Visvikis D; Gee AD; Groves AM; Kenny LM; Cook GJ; Kinahan PE; Myers M; Clarke L;
    Eur Radiol; 2012 Jul; 22(7):1465-78. PubMed ID: 22476502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic features of clear-cell renal cell carcinoma: mechanisms and clinical implications.
    Pinthus JH; Whelan KF; Gallino D; Lu JP; Rothschild N
    Can Urol Assoc J; 2011 Aug; 5(4):274-82. PubMed ID: 21801687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted therapies in renal cell cancer: recent developments in imaging.
    van der Veldt AA; Meijerink MR; van den Eertwegh AJ; Boven E
    Target Oncol; 2010 Jun; 5(2):95-112. PubMed ID: 20625845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional imaging of renal cell carcinoma.
    Lawrentschuk N; Davis ID; Bolton DM; Scott AM
    Nat Rev Urol; 2010 May; 7(5):258-66. PubMed ID: 20448659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel imaging modalities in gynecologic cancer.
    Brooks RA; Powell MA
    Curr Oncol Rep; 2009 Nov; 11(6):466-72. PubMed ID: 19840524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of SU5416, a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR) in refractory pediatric central nervous system tumors.
    Kieran MW; Supko JG; Wallace D; Fruscio R; Poussaint TY; Phillips P; Pollack I; Packer R; Boyett JM; Blaney S; Banerjee A; Geyer R; Friedman H; Goldman S; Kun LE; Macdonald T;
    Pediatr Blood Cancer; 2009 Feb; 52(2):169-76. PubMed ID: 19065567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical biomarkers of angiogenesis inhibition.
    Brown AP; Citrin DE; Camphausen KA
    Cancer Metastasis Rev; 2008 Sep; 27(3):415-34. PubMed ID: 18414993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promise and progress for functional and molecular imaging of response to targeted therapies.
    Stephen RM; Gillies RJ
    Pharm Res; 2007 Jun; 24(6):1172-85. PubMed ID: 17385018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points.
    O'Donnell A; Padhani A; Hayes C; Kakkar AJ; Leach M; Trigo JM; Scurr M; Raynaud F; Phillips S; Aherne W; Hardcastle A; Workman P; Hannah A; Judson I
    Br J Cancer; 2005 Oct; 93(8):876-83. PubMed ID: 16222321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complete radiological and metabolic response of metastatic renal cell carcinoma to SU5416 (semaxanib) in a patient with probable von Hippel-Lindau syndrome.
    Jennens RR; Rosenthal MA; Lindeman GJ; Michael M
    Urol Oncol; 2004; 22(3):193-6. PubMed ID: 15271314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma.
    Kuenen BC; Tabernero J; Baselga J; Cavalli F; Pfanner E; Conte PF; Seeber S; Madhusudan S; Deplanque G; Huisman H; Scigalla P; Hoekman K; Harris AL
    Clin Cancer Res; 2003 May; 9(5):1648-55. PubMed ID: 12738717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status.
    Rini BI; Jaeger E; Weinberg V; Sein N; Chew K; Fong K; Simko J; Small EJ; Waldman FM
    BJU Int; 2006 Oct; 98(4):756-62. PubMed ID: 16827904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding the importance of smart drugs in renal cell carcinoma.
    Patard JJ; Rioux-Leclercq N; Fergelot P
    Eur Urol; 2006 Apr; 49(4):633-43. PubMed ID: 16481093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A case of renal cell carcinoma associated with von Hippel-Lindau disease and the necessity for family genetic diagnosis].
    Nanri M; Uda M; Iguchi Y; Gouya N; Toma H; Kihara T
    Hinyokika Kiyo; 1999 Nov; 45(11):755-8. PubMed ID: 10637737
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.